Coherus Oncology, Inc.
NASDAQ:CHRSBiotechnology
+$0.03 today
- Market cap
- $63.35M
- Beta
- 0.96
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.11
Volume 2.55M
Average 1.15M
CHRS EBITDA Margin
EBITDA as a percentage of revenue.
Coherus Oncology, Inc.NASDAQ: CHRS
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -275.1%
EBITDA Margin was -275.1% in Q1 FY2026, up 306.6 pp from a year earlier. On a trailing-twelve-month basis it was -341.0%, down 291.0 pp year over year. Over 3 fiscal years it narrowed by 282.5 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 5 analysts of -127.0% for the fiscal year ending Dec 2026, up from -403.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -275.1%+63.8 pp QoQ
- Last fiscal yearDec 2025
- -403.6%-426.4 pp YoY
- LTMMar 2026
- -341.0%-291.0 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -403.6%
- Year-over-year change
- -426.4pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -403.6% | -426.4pp |
| FY2024 | 2024-12-31 | 22.8% | +98.2pp |
| FY2023 | 2023-12-31 | -75.4% | +45.7pp |
| FY2022 | 2022-12-31 | -121.1% | -41.3pp |
| FY2021 | 2021-12-31 | -79.8% | — |
EBITDA Margin vs competitors
How CHRS compares with its peers on the latest reported figures
- CHRS's LTM Mar 2026 EBITDA Margin of -341.0% is the 7th highest of the 9 companies compared; the peer median is -211.7%.
- Its year-over-year change of -291.0 pp is the 7th highest of 9, against a peer median of -13.7 pp.
- Over three fiscal years its change of -282.5 pp compares with a peer median of -29.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 29.2% | +17.2 pp | +17.0 pp | |
| LTM Mar 2026 | -28.2% | +91.2 pp | -29.1 pp | |
| LTM Mar 2026 | -117.0% | +50.4 pp | -225.4 pp | |
| LTM Mar 2026 | -135.5% | +244.4 pp | — | |
| LTM Mar 2026 | -287.9% | -44.6 pp | +113.4 pp | |
| LTM Mar 2026 | -339.9% | -229.0 pp | -131.5 pp | |
| LTM Mar 2026 | -341.0% | -291.0 pp | -282.5 pp | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | -2329.5% | -862.2 pp | +207.6 pp |
| LTM Mar 2026 | -142957.6% | -159600.9 pp | -131573.1 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding CHRS) | -211.7% | -13.7 pp | -29.1 pp | |
Competitors are the stored peer set for CHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 326.55M | 211.04M | 257.24M | 266.96M | 42.17M |
| Cost of Revenue | 57.59M | 70.08M | 158.99M | 117.55M | 17.74M |
| Gross Profit | 268.96M | 140.96M | 98.25M | 149.41M | 24.43M |
| Gross Margin | 82.4% | 66.8% | 38.2% | 56.0% | 57.9% |
| Research & Development | 363.11M | 199.36M | 109.44M | 93.34M | 104.96M |
| Selling, General & Admin | 169.71M | 198.48M | 185.62M | 150.44M | 99M |
| Operating Expenses | 532.82M | 397.84M | 301.45M | 261.07M | 203.97M |
| Depreciation & Amortization | 3.45M | 3.7M | 3.79M | 5.28M | 3.92M |
| EBITDA | (260.69M) | (255.58M) | (193.94M) | 60.94M | (170.2M) |
| EBITDA Margin | -79.8% | -121.1% | -75.4% | 22.8% | -403.6% |
| Operating Income | (263.86M) | (256.88M) | (203.2M) | (111.67M) | (179.53M) |
| Operating Margin | -80.8% | -121.7% | -79.0% | -41.8% | -425.7% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 22.96M | 32.47M | 40.54M | 27.16M | 9M |
| Other Income / Expenses | (23.24M) | (34.87M) | (35.07M) | 140.17M | (3.59M) |
| Income Before Tax | (287.1M) | (291.75M) | (238.27M) | 28.51M | (183.12M) |
| Pre-Tax Margin | -87.9% | -138.2% | -92.6% | 10.7% | -434.2% |
| Income Tax Expense | 0 | 0 | (380K) | 0 | 0 |
| Net Income | (287.1M) | (291.75M) | (237.89M) | 28.51M | (170.29M) |
| Net Margin | -87.9% | -138.2% | -92.5% | 10.7% | -403.8% |
| EPS (Basic) | (3.81) | (3.76) | (2.53) | 0.25 | (1.45) |
| EPS (Diluted) | (3.81) | (3.76) | (2.53) | 0.25 | (1.45) |
| Weighted Avg Shares | 75.45M | 77.63M | 94.16M | 114.55M | 120.37M |
| Weighted Avg Shares (Diluted) | 75.45M | 77.63M | 94.16M | 114.83M | 120.37M |
Coherus Oncology, Inc.
NASDAQ:CHRS
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.